11:36 AM EDT, 03/20/2024 (MT Newswires) -- PharmAla Biotech Holdings Inc. ( MDXXF ) focused on the research, development, and manufacturing of LaNeo MDMA and novel derivatives of MDMA (MDXX class molecules), announces that allowance has been granted for the Composition of Matter of its PharmAla-1 (P-1) molecule by the US Patent and Trademark Office (USPTO).

"In proof-of-concept rodent models at the laboratory of Prof. William Fantegrossi, P-1 showed a number of features which we believe to be extremely valuable in a therapeutic context," said Dr. Harpreet Kaur, Vice President of Research at PharmAla Biotech ( MDXXF ). "The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA. We also believe it can induce neuroplasticity, like many drugs in the tryptamine class, by crossing the cell membrane and binding to serotonin receptors within the cell. And of course, like all the molecules we choose to develop, P-1 has an excellent safety profile with low abuse liability."

Price: 0.17, Change: +0.02, Percent Change: +9.68